Batu Biologics is an immuno-oncology company focused on the development and commercialization of novel therapies that target the Achilles Heel of cancer: the tumor blood vessels. The company has recently launched an equity crowdfunding campaign seeking investment from accredited investors to bring our tumor angiogenesis targeting immune therapy into the clinic in the United States. Please watch the video below to learn more about our approach to treating and potentially curing cancer.


Our Belief

At Batu Biologics we believe the most potent medicines are to be found within the patient’s body, the key is to unleash them. Our products are centered around the idea of creating or breaking immune tolerance. The company is currently in the preclinical stage of drug development for its flagship products: Vallovax™. Batu Biologics has also recently exclusively licensed vaccine adjuvant technology from UC San Diego.

Who We Are

Batu Biologics is a biopharmaceutical company based in San Diego seeking to rapidly translate novel cell and gene therapies for the treatment of cancer. Batu is focused on developing the “ValloVax™” platform, an allogeneic and universal donor cellular vaccine designed to stimulate a targeted immune response against the blood vessels of the tumor for a wide array of cancers.

Activities

• Research of cancer immunotherapy

• Preclinical development of ValloVax™

• IP expansion and licensing opportunities

• Contractual Research

• Academic Collaborations


Latest News & Events:

Batu Biologics Launches #starvethetumor Crowdfunding Campaign for ValloVax Immunotherapy

Batu Biologics has launched an equity crowdfunding campaign open to accredited investors that will help secure clinical approval for the ValloVax platform with the Food and Drug Administration.

More information